Global /India /Healthcare /Drug Manufacturers - General /531210
chevron_leftBack
Colinz Laboratories Ltd. logo

Colinz Laboratories Ltd.

531210
BSE: 531210 Delayed
47.84INR 4%
0.5067 USD
As of 20 June 2026, Colinz Laboratories Ltd. has a market cap of $1.28M USD, ranking #48164 globally and #4911 in India. It ranks #4270 in the Healthcare sector, and #1348 in the Drug Manufacturers - General industry.
Global Rank
48164
Country Rank
4911
Sector Rank
4270
Industry Rank
1348
Key Stats
Market Cap
$1.28MUSD
120.51M INR
Enterprise Value
$560.4KUSD
52.91M INR
Revenue (TTM)
$618.7KUSD
58.4M INR
EBITDA (TTM)
$41.83KUSD
3.95M INR
Net Income (TTM)
$52.31KUSD
4.94M INR
EBITDA Margin
6.8%
Profit Margin
8.5%
PE Ratio
24.4
PS Ratio
2.1
PB Ratio
1.2
EV/EBITDA
13.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Narayanan Menon open_in_new
Employees
65
Founded
1986
Website
colinz.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
4% 0.4% 5.8% -31% 16% -19%

News

Loading...

Markets

Exchange Ticker Price
Bombay Stock Exchange
MIC: XBOM
PRIMARY
531210 (COLINZ)
Colinz Laboratories Ltd
ISIN: INE923C01011
Shares Out.:
2.519M1
TV:
SA:
YF:
GF:
BA:
MS:
47.84 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Colinz Laboratories Ltd.

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. Further, it provides nutraceuticals, including spirulina tabs/caps, spirulina with vitamins and minerals, omega 3 fatty acids caps in softgel, codliver oil with vitamin caps in soft gel, amino acids tabs/caps, l-arginine with proantocyanidin granules, and hair growth formulations, etc., as well as collagen, glucosamine, and chondroitin tabs. Colinz Laboratories Limited was incorporated in 1986 and is based in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - General (India)
Name
Market Cap diff.
PE
$45.22B
4.27T INR
4M%
39.1
DIVISLAB
$18.38B
1.73T INR
1M%
70.0
$15.17B
1.43T INR
1M%
63.0
$11.73B
1.11T INR
919K%
19.6
MANKIND
$9.87B
931.67B INR
773K%
52.2
ZYDUSLIFE
$9.71B
916.53B INR
760K%
18.6
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
60M%
38.1
JNJ
$547.28B
43M%
26.4
ABBV
$360.63B
28M%
97.4
$318.3B
256.25B CHF
25M%
19.9
AZN
$284.64B
215.59B GBP
22M%
27.6
MRK
$274.03B
21M%
15.1
chevron_leftBack